1	Rofecoxib	Rofecoxib	B-NP	NN	O	0	ROOT	0
2	as	as	B-PP	IN	O	1	NMOD	0
3	adjunctive	adjunctive	B-NP	JJ	O	4	NMOD	0
4	therapy	therapy	I-NP	NN	O	2	PMOD	0
5	for	for	B-PP	IN	O	4	NMOD	0
6	haemophilic	haemophilic	B-NP	JJ	O	7	NMOD	0
7	arthropathy	arthropathy	I-NP	NN	O	5	PMOD	0
8	.	.	O	.	O	1	P	0

1	Joint	Joint	B-NP	NN	O	2	NMOD	0
2	haemorrhage	haemorrhage	I-NP	NN	O	6	NMOD	0
3	and	and	O	CC	O	6	NMOD	0
4	subsequent	subsequent	B-NP	JJ	O	6	NMOD	0
5	haemophilic	haemophilic	I-NP	JJ	O	6	NMOD	0
6	arthropathy	arthropathy	I-NP	NN	O	7	SUB	0
7	are	be	B-VP	VBP	O	0	ROOT	0
8	significant	significant	B-NP	JJ	O	9	NMOD	0
9	complications	complication	I-NP	NNS	O	7	PRD	0
10	in	in	B-PP	IN	O	9	NMOD	0
11	haemophilia	haemophilia	B-NP	NN	O	10	PMOD	0
12	.	.	O	.	O	7	P	0

1	The	The	B-NP	DT	O	2	NMOD	0
2	pathophysiology	pathophysiology	I-NP	NN	O	3	SUB	0
3	involves	involve	B-VP	VBZ	O	0	ROOT	0
4	inflammation	inflammation	B-NP	NN	O	6	NMOD	0
5	and	and	I-NP	CC	O	6	NMOD	0
6	angiogenesis	angiogenesis	I-NP	NN	O	3	OBJ	3	angiogenesis
7	.	.	O	.	O	3	P	0

1	Cyclooxygenase-2	Cyclooxygenase-2	B-NP	NN	B-protein	5	NMOD	0
2	(	(	O	(	O	4	DEP	0
3	COX-2	COX-2	B-NP	NN	B-protein	4	DEP	0
4	)	)	O	)	O	1	NMOD	0
5	inhibitors	inhibitor	B-NP	NNS	O	6	SUB	0
6	are	be	B-VP	VBP	O	0	ROOT	0
7	anti-inflammatory	anti-inflammatory	B-NP	JJ	O	8	NMOD	0
8	agents	agent	I-NP	NNS	O	6	PRD	0
9	,	,	O	,	O	8	P	0
10	which	which	B-NP	WDT	O	8	NMOD	0
11	have	have	B-VP	VBP	O	10	SBAR	0
12	potent	potent	B-NP	JJ	O	17	AMOD	0
13	anti-inflammatory	anti-inflammatory	I-NP	JJ	O	17	AMOD	0
14	,	,	I-NP	,	O	17	P	0
15	anti-angiogenic	anti-angiogenic	I-NP	JJ	O	17	AMOD	3	angiogenic
16	and	and	I-NP	CC	O	17	AMOD	0
17	analgesic	analgesic	I-NP	JJ	O	18	NMOD	0
18	properties	property	I-NP	NNS	O	11	OBJ	18	properties
19	yet	yet	B-ADVP	RB	O	6	VMOD	0
20	do	do	B-VP	VBP	O	6	VMOD	0
21	not	not	I-VP	RB	O	20	VMOD	0
22	affect	affect	I-VP	VB	O	20	VC	16	affect
23	platelet	platelet	B-NP	NN	O	24	NMOD	0
24	function	function	I-NP	NN	O	22	OBJ	0
25	in	in	B-PP	IN	O	22	VMOD	0
26	the	the	B-NP	DT	O	27	NMOD	0
27	manner	manner	I-NP	NN	O	25	PMOD	0
28	of	of	B-PP	IN	O	27	NMOD	0
29	traditional	traditional	B-NP	JJ	O	32	NMOD	0
30	non-steroidal	non-steroidal	I-NP	JJ	O	32	NMOD	0
31	anti-inflammatory	anti-inflammatory	I-NP	JJ	O	32	NMOD	0
32	drugs	drug	I-NP	NNS	O	28	PMOD	0
33	.	.	O	.	O	6	P	0

1	These	These	B-NP	DT	O	2	NMOD	0
2	properties	property	I-NP	NNS	O	3	SUB	0
3	make	make	B-VP	VBP	O	0	ROOT	0
4	such	such	B-NP	JJ	O	5	NMOD	0
5	agents	agent	I-NP	NNS	O	3	OBJ	0
6	potentially	potentially	B-ADJP	RB	O	7	AMOD	0
7	useful	useful	I-ADJP	JJ	O	5	NMOD	0
8	as	as	B-PP	IN	O	7	AMOD	0
9	adjunctive	adjunctive	B-NP	JJ	O	10	NMOD	0
10	therapy	therapy	I-NP	NN	O	8	PMOD	0
11	in	in	B-PP	IN	O	10	NMOD	0
12	haemophilia	haemophilia	B-NP	NN	O	11	PMOD	0
13	.	.	O	.	O	3	P	0

1	There	There	B-NP	EX	O	2	SUB	0
2	is	be	B-VP	VBZ	O	0	ROOT	0
3	only	only	B-NP	RB	O	6	NMOD	0
4	one	one	I-NP	CD	O	3	AMOD	0
5	prior	prior	I-NP	JJ	O	6	NMOD	0
6	report	report	I-NP	NN	O	2	PRD	0
7	describing	describe	B-VP	VBG	O	6	NMOD	0
8	rofecoxib	rofecoxib	B-NP	NN	O	9	NMOD	0
9	treatment	treatment	I-NP	NN	O	7	OBJ	19	treatment
10	in	in	B-PP	IN	O	9	NMOD	0
11	a	a	B-NP	DT	O	14	NMOD	0
12	single	single	I-NP	JJ	O	14	NMOD	0
13	haemophilia	haemophilia	I-NP	NN	O	14	NMOD	0
14	patient	patient	I-NP	NN	O	10	PMOD	0
15	.	.	O	.	O	2	P	0

1	Our	Our	B-NP	PRP$	O	2	NMOD	0
2	objectives	objective	I-NP	NNS	O	3	SUB	0
3	were	be	B-VP	VBD	O	0	ROOT	0
4	to	to	I-VP	TO	O	5	VMOD	0
5	determine	determine	I-VP	VB	O	3	VMOD	0
6	the	the	B-NP	DT	O	9	NMOD	0
7	safety	safety	I-NP	NN	O	9	NMOD	0
8	and	and	I-NP	CC	O	9	NMOD	0
9	efficacy	efficacy	I-NP	NN	O	5	OBJ	0
10	of	of	B-PP	IN	O	9	NMOD	0
11	rofecoxib	rofecoxib	B-NP	NN	O	10	PMOD	0
12	in	in	B-PP	IN	O	9	NMOD	0
13	treating	treat	B-VP	VBG	O	12	PMOD	19	treating
14	acute	acute	B-NP	JJ	O	15	NMOD	0
15	haemarthrosis	haemarthrosis	I-NP	NN	O	13	OBJ	0
16	,	,	O	,	O	23	P	0
17	chronic	chronic	B-NP	JJ	O	18	NMOD	0
18	synovitis	synovitis	I-NP	NN	O	23	NMOD	0
19	,	,	O	,	O	23	P	0
20	target	target	B-NP	NN	O	21	NMOD	0
21	joints	joint	I-NP	NNS	O	23	NMOD	0
22	and	and	O	CC	O	23	NMOD	0
23	pain	pain	B-NP	NN	O	5	VMOD	0
24	.	.	O	.	O	3	P	0

1	We	We	B-NP	PRP	O	2	SUB	0
2	conducted	conduct	B-VP	VBD	O	0	ROOT	0
3	a	a	B-NP	DT	O	7	NMOD	0
4	retrospective	retrospective	I-NP	JJ	O	7	NMOD	0
5	medical	medical	I-NP	JJ	O	7	NMOD	0
6	record	record	I-NP	NN	O	7	NMOD	0
7	review	review	I-NP	NN	O	23	NMOD	0
8	of	of	B-PP	IN	O	7	NMOD	0
9	patients	patient	B-NP	NNS	O	8	PMOD	0
10	treated	treat	B-VP	VBN	O	9	NMOD	19	treated
11	with	with	B-PP	IN	O	10	VMOD	0
12	rofecoxib	rofecoxib	B-NP	NN	O	11	PMOD	0
13	for	for	B-PP	IN	O	10	VMOD	0
14	acute	acute	B-NP	JJ	O	15	NMOD	0
15	haemarthrosis	haemarthrosis	I-NP	NN	O	13	PMOD	0
16	,	,	O	,	O	23	P	0
17	chronic	chronic	B-NP	JJ	O	18	NMOD	0
18	synovitis	synovitis	I-NP	NN	O	23	NMOD	0
19	,	,	O	,	O	23	P	0
20	target	target	B-NP	NN	O	21	NMOD	0
21	joint	joint	I-NP	NN	O	23	NMOD	0
22	or	or	I-NP	CC	O	23	NMOD	0
23	pain	pain	I-NP	NN	O	2	OBJ	0
24	.	.	O	.	O	2	P	0

1	The	The	B-NP	DT	O	4	NMOD	0
2	safety	safety	I-NP	NN	O	4	NMOD	0
3	and	and	I-NP	CC	O	4	NMOD	0
4	efficacy	efficacy	I-NP	NN	O	8	SUB	0
5	of	of	B-PP	IN	O	4	NMOD	0
6	rofecoxib	rofecoxib	B-NP	NN	O	7	NMOD	0
7	treatment	treatment	I-NP	NN	O	5	PMOD	19	treatment
8	were	be	B-VP	VBD	O	0	ROOT	0
9	determined	determine	I-VP	VBN	O	8	VC	0
10	based	base	B-PP	VBN	O	9	VMOD	0
11	on	on	B-PP	IN	O	10	PMOD	0
12	subjective	subjective	B-NP	JJ	O	14	NMOD	0
13	patient	patient	I-NP	NN	O	14	NMOD	0
14	reports	report	I-NP	NNS	O	17	NMOD	0
15	and	and	O	CC	O	17	NMOD	0
16	physical	physical	B-NP	JJ	O	17	NMOD	0
17	examinations	examination	I-NP	NNS	O	11	PMOD	0
18	during	during	B-PP	IN	O	17	NMOD	0
19	follow-up	follow-up	B-NP	JJ	O	21	NMOD	0
20	clinic	clinic	I-NP	NN	O	21	NMOD	0
21	visits	visit	I-NP	NNS	O	18	PMOD	0
22	.	.	O	.	O	8	P	0

1	A	A	B-NP	DT	O	2	NMOD	0
2	total	total	I-NP	NN	O	13	SUB	0
3	of	of	B-PP	IN	O	2	NMOD	0
4	28	28	B-NP	CD	O	5	NMOD	0
5	patients	patient	I-NP	NNS	O	3	PMOD	0
6	between	between	B-PP	IN	O	5	NMOD	0
7	3	3	B-NP	CD	O	9	AMOD	0
8	and	and	I-NP	CC	O	9	AMOD	0
9	37	37	I-NP	CD	O	10	NMOD	0
10	years	year	I-NP	NNS	O	6	PMOD	0
11	of	of	B-PP	IN	O	10	NMOD	0
12	age	age	B-NP	NN	O	11	PMOD	0
13	were	be	B-VP	VBD	O	0	ROOT	0
14	treated	treat	I-VP	VBN	O	13	VC	19	treated
15	for	for	B-PP	IN	O	14	VMOD	0
16	a	a	B-NP	DT	O	17	NMOD	0
17	total	total	I-NP	NN	O	15	PMOD	0
18	of	of	B-PP	IN	O	17	NMOD	0
19	42	42	B-NP	CD	O	20	NMOD	0
20	courses	course	I-NP	NNS	O	18	PMOD	0
21	of	of	B-PP	IN	O	20	NMOD	0
22	rofecoxib	rofecoxib	B-NP	NN	O	23	NMOD	0
23	treatment	treatment	I-NP	NN	O	21	PMOD	19	treatment
24	.	.	O	.	O	13	P	0

1	All	All	B-NP	DT	O	2	NMOD	0
2	courses	course	I-NP	NNS	O	3	SUB	0
3	were	be	B-VP	VBD	O	0	ROOT	0
4	evaluated	evaluate	I-VP	VBN	O	3	VC	0
5	for	for	B-PP	IN	O	4	VMOD	0
6	safety	safety	B-NP	NN	O	8	NMOD	0
7	and	and	O	CC	O	8	NMOD	0
8	31	31	B-NP	CD	O	5	PMOD	0
9	for	for	B-PP	IN	O	8	NMOD	0
10	efficacy	efficacy	B-NP	NN	O	9	PMOD	0
11	.	.	O	.	O	3	P	0

1	Rofecoxib	Rofecoxib	B-NP	NN	O	2	SUB	0
2	was	be	B-VP	VBD	O	0	ROOT	0
3	used	use	I-VP	VBN	O	2	VC	19	used
4	for	for	B-PP	IN	O	3	VMOD	0
5	eight	eight	B-NP	CD	O	7	NMOD	0
6	acute	acute	I-NP	JJ	O	7	NMOD	0
7	haemarthrosis	haemarthrosis	I-NP	NN	O	4	PMOD	0
8	,	,	O	,	O	14	P	0
9	four	four	B-NP	CD	O	11	NMOD	0
10	target	target	I-NP	NN	O	11	NMOD	0
11	joints	joint	I-NP	NNS	O	14	NMOD	0
12	,	,	O	,	O	14	P	0
13	seven	seven	B-NP	CD	O	14	NMOD	0
14	cases	case	I-NP	NNS	O	7	NMOD	0
15	of	of	B-PP	IN	O	14	NMOD	0
16	synovitis	synovitis	B-NP	NN	O	19	NMOD	0
17	and	and	O	CC	O	19	NMOD	0
18	12	12	B-NP	CD	O	19	NMOD	0
19	episodes	episode	I-NP	NNS	O	15	PMOD	0
20	of	of	B-PP	IN	O	19	NMOD	0
21	pain	pain	B-NP	NN	O	20	PMOD	0
22	.	.	O	.	O	2	P	0

1	Efficacy	Efficacy	B-NP	NN	O	2	SUB	0
2	was	be	B-VP	VBD	O	15	VMOD	0
3	demonstrated	demonstrate	I-VP	VBN	O	2	VC	0
4	particularly	particularly	B-ADVP	RB	O	3	VMOD	0
5	for	for	B-PP	IN	O	3	VMOD	0
6	chronic	chronic	B-NP	JJ	O	7	NMOD	0
7	synovitis	synovitis	I-NP	NN	O	9	NMOD	0
8	and	and	I-NP	CC	O	9	NMOD	0
9	pain	pain	I-NP	NN	O	5	PMOD	0
10	and	and	O	CC	O	15	VMOD	0
11	no	no	B-NP	DT	O	14	NMOD	0
12	serious	serious	I-NP	JJ	O	13	AMOD	0
13	adverse	adverse	I-NP	JJ	O	14	NMOD	0
14	events	event	I-NP	NNS	O	15	SUB	0
15	occurred	occur	B-VP	VBD	O	0	ROOT	0
16	.	.	O	.	O	15	P	0

1	This	This	B-NP	DT	O	2	SUB	0
2	is	be	B-VP	VBZ	O	0	ROOT	0
3	the	the	B-NP	DT	O	5	NMOD	0
4	largest	large	I-NP	JJS	O	5	NMOD	0
5	study	study	I-NP	NN	O	2	PRD	0
6	to	to	B-PP	TO	O	5	NMOD	0
7	date	date	B-NP	NN	O	6	PMOD	0
8	evaluating	evaluate	B-VP	VBG	O	5	NMOD	0
9	COX-2	COX-2	B-NP	NN	B-protein	10	NMOD	0
10	inhibitors	inhibitor	I-NP	NNS	O	8	OBJ	0
11	as	as	B-PP	IN	O	8	VMOD	0
12	adjunctive	adjunctive	B-NP	JJ	O	13	NMOD	0
13	therapy	therapy	I-NP	NN	O	11	PMOD	0
14	in	in	B-PP	IN	O	13	NMOD	0
15	haemophilia	haemophilia	B-NP	NN	O	14	PMOD	0
16	and	and	O	CC	O	2	VMOD	0
17	suggests	suggest	B-VP	VBZ	O	2	VMOD	0
18	that	that	B-SBAR	IN	O	17	VMOD	0
19	these	these	B-NP	DT	O	20	NMOD	0
20	agents	agent	I-NP	NNS	O	21	SUB	0
21	may	may	B-VP	MD	O	18	SBAR	0
22	be	be	I-VP	VB	O	21	VC	0
23	an	an	B-NP	DT	O	26	NMOD	0
24	important	important	I-NP	JJ	O	26	NMOD	0
25	adjunctive	adjunctive	I-NP	JJ	O	26	NMOD	0
26	therapy	therapy	I-NP	NN	O	22	PRD	0
27	in	in	B-PP	IN	O	26	NMOD	0
28	the	the	B-NP	DT	O	29	NMOD	0
29	management	management	I-NP	NN	O	27	PMOD	0
30	of	of	B-PP	IN	O	29	NMOD	0
31	haemophilia	haemophilia	B-NP	NN	O	30	PMOD	0
32	.	.	O	.	O	2	P	0

